BIP Trial

Revision as of 22:49, 17 September 2013 by Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==BIP Trial== * This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events. * ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

BIP Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of BIP Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on BIP Trial

CDC on BIP Trial

BIP Trial in the news

Blogs on BIP Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for BIP Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

BIP Trial

  • This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events.
  • Bezafibrate raised the HDL levels and decreased the triglyceride levels in patients with a previous myocardial infarction or stable angina. An overall reduction in the risk of cardiovascular events was noted.[1]

References

  1. "Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study". Circulation. 102 (1): 21–7. 2000. PMID 10880410. Unknown parameter |month= ignored (help)